Phorbol Ester Composition for ARDS Hyperinflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Acute Respiratory Distress Syndrome (ARDS) and related inflammatory disorders caused by viral pathogens like SARS coronaviruses, such as COVID-19, are inadequate, with no effective methods to prevent or substantially reduce mortality, and existing anti-inflammatory therapies pose risks and uncertainties regarding efficacy and side effects.
Innovation Solution
The use of TPA compounds, specifically phorbol esters and derivatives, to treat and prevent ARDS and hyperinflammatory conditions by targeting multiple pathways, including Cytokine Storm Syndrome (CSS), Pediatric Inflammatory Multisystem Syndrome (PIMS), and other inflammatory diseases, while minimizing impairment to beneficial immune functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If existing anti-inflammatory therapies are used to treat ARDS and hyperinflammatory conditions, then inflammation is reduced, but beneficial immune functions are impaired and side effects occur
Solution Approach 1:
The patent employs TPA compounds as intermediary substances that specifically target and modulate hyperinflammatory pathways (such as NF-κB and cytokine release) without broadly suppressing the immune system. These compounds act as selective mediators between the harmful inflammatory response and the beneficial immune functions, reducing inflammation while preserving immune competence through pathway-specific inhibition rather than general immunosuppression.
Solution Approach 2:
The invention utilizes TPA compounds to change the parameters of immune response regulation by modulating specific signaling pathways (NF-κB, MAPK, cytokine networks) at molecular levels. This allows precise adjustment of inflammatory parameters (cytokine levels, immune cell activation) while maintaining other immune parameters intact, achieving selective control over the inflammatory response without broad immune suppression.
2Reliability
If no effective treatment is available for ARDS caused by SARS coronaviruses, then viral infection progresses unchecked, but mortality and morbidity increase
Solution Approach 1:
The patent converts the harmful hyperinflammatory response caused by SARS coronavirus infection into a beneficial therapeutic target. By identifying and treating the cytokine storm and hyperinflammation as the primary drivers of mortality rather than the viral infection itself, the invention transforms the body's excessive defensive response (harmful) into a treatable condition (beneficial), using anti-inflammatory TPA compounds to neutralize the harmful effects while allowing controlled immune response.
3Object-affected harmful factors
If broad anti-inflammatory approaches are used, then inflammation is suppressed, but viral clearance and beneficial immune responses are impaired
Solution Approach 1:
The patent segments the immune response into distinct functional components: beneficial antiviral immunity and harmful hyperinflammation. TPA compounds selectively target and suppress only the harmful hyperinflammatory segment (cytokine storm, excessive neutrophil activation, tissue-damaging inflammation) while leaving the beneficial antiviral segment (viral clearance, adaptive immunity) intact. This segmentation allows differential control over immune functions based on their therapeutic value.
Solution Approach 2:
TPA compounds serve as selective intermediaries that intervene in specific hyperinflammatory pathways (NF-κB, cytokine release, neutrophil activation) without blocking general immune function. These intermediary substances provide pathway-specific modulation, allowing viral clearance mechanisms to operate while preventing excessive inflammatory damage through targeted molecular intervention.
Data Source
AI summary
Methods and compositions containing a phorbol ester or derivative of a phorbol ester are provided for prevention and treatment of sudden acute respiratory syndrome (SARS) coronavirus infection, including SARS-COV-2 infection and related COVID-19 disease. Also provided are methods and compositions for preventing and treating acute inflammatory conditions and related pathogenic injuries, including Acute Respiratory Distress Syndrome (ARDS) and cytokine storm syndrome (CSS) seen in severe SARS-COV-2/COVID-19 cases.